UCHL5IP Blocking Peptide
- Known as:
- UCHL5IP Blocking Peptide
- Catalog number:
- 33r-5125
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- UCHL5IP Blocking Peptide
Related genes to: UCHL5IP Blocking Peptide
- Gene:
- HAUS7 NIH gene
- Name:
- HAUS augmin like complex subunit 7
- Previous symbol:
- UCHL5IP
- Synonyms:
- UIP1
- Chromosome:
- Xq28
- Locus Type:
- gene with protein product
- Date approved:
- 2006-10-30
- Date modifiied:
- 2016-01-15
Related products to: UCHL5IP Blocking Peptide
Related articles to: UCHL5IP Blocking Peptide
- Is exome sequencing (ES) an efficient approach for simultaneous analysis of causative single gene defects and copy number variants (CNV) in unexplained premature ovarian insufficiency (POI)? - Source: PubMed
Publication date: 2026/06/17
Valkna AnuKikas TriinJakovlev ÜlleMõttus OliverDutta AvirupErlang KülliPunab MargusRull KristiinaLaan Maris - - Source: PubMed
Publication date: 2026/02/28
Kiyota NaokiNamekata Kazuhiko - The molecular mechanisms involved in reconstructing the eye-to-brain connection and functional recovery following optic nerve damage remain unclear. This study revealed that HAUS augmin-like complex subunit 7 (HAUS7) is a molecule that binds to dedicator of cytokinesis 3 (DOCK3), a regulator of neurotrophic factor signaling and axon regeneration. We observed a distribution pattern of HAUS7 expression, suggesting that neuronal HAUS7 is transported from the cell body to the growth cone under the control of DOCK3. In addition, phosphorylation of DOCK3 at Y562 by tropomyosin receptor kinase B signaling leads to the dissociation of HAUS7, which is considered an important step for microtubule assembly. Deletion of in mice significantly reduced microtubule formation and axon regeneration following optic nerve crush (ONC). Transcriptome analysis suggested that HAUS7 levels decrease in glaucoma and after the ONC, while retinal ganglion cells actively regenerating their axons express high levels of HAUS7. In summary, HAUS7 is a binding partner of DOCK3 necessary for axon elongation. - Source: PubMed
Publication date: 2025/07/25
Kiyota NaokiShinozaki YouichiGuo XiaoliKimura AtsukoKawamura KazutoNishijima EuidoHonda SariHarada ChikakoNakazawa ToruNamekata KazuhikoHarada Takayuki - Head and neck squamous cell carcinoma (HNSCC) is one of the major types of cancer, with 900,000 cases and over 400,000 deaths annually. It constitutes 3-4% of all cancers in Europe and western countries. As early diagnosis is the key to treating the disease, reliable biomarkers play an important role in the precision medicine of HNSCC. Despite treatments, the survival rate of cancer patients remains unchanged, and this is mainly due to the failure to detect the disease early. Thus, the objective of this study is to identify reliable biomarkers for head and neck cancers for better healthcare management. In this study, all available, curated human genes were screened for their expression against HNSCC TCGA patient samples using genomic and proteomic data by various bioinformatic approaches and datamining. Docking studies were performed using AutoDock or online virtual screening tools for identifying potential ligands. Sixty genes were short-listed, and most of them show a consistently higher expression in head and neck patient samples at both the mRNA and the protein level. Irrespective of human papillomavirus (HPV) status, all of them show a higher expression in cancer samples. The higher expression of 30 genes shows adverse effects on patient survival. Out of the 60 genes, 12 genes have crystal structures and druggable potential. We show that genes such as GTF2H4, HAUS7, MSN, and MNDA could be targets of Pembrolizumab and Nivolumab, which are approved monoclonal antibodies for HNSCC. Sixty genes are identified as potential biomarkers for head and neck cancers based on their consistent and statistically significantly higher expression in patient samples. Four proteins have been identified as potential drug targets based on their crystal structure. However, the utility of these candidate genes has to be further tested using patient samples. - Source: PubMed
Publication date: 2024/03/07
Kunhabdulla HafeedaManas RamShettihalli Ashok KumarReddy Ch Ram MohanMustak Mohammed SJetti RaghuAbdulla RiazSirigiri Divijendranatha ReddyRamdan DedenAmmarullah Muhammad Imam - Gliomas are the most prevalent primary tumors in the central nervous system. Despite some breakthroughs in the treatment of glioma in recent years, survival rates remain low. Although genes of the Augmin family play a key role in microtubule nucleation, the role they play in gliomas is unclear. Transcriptome data were extracted from UCSC XENA and GTEx for low-grade glioma (LGG) and normal tissues, respectively. The protein interaction network associated with Augmin family genes was established using STRING and GeneMANIA databases. Enrichment analysis of gene-related functions and pathways was used to explore potential biological pathways and TIMER to assess immune cell infiltration. Regression analysis and Kaplan-Meier analysis were used to look at the clinical characteristics of the Augmin family genes and the association with the prognosis of patients with glioma. The results showed that the mRNA expression of Augmin family genes was significantly elevated in LGG tissues, except for HAUS7. Immunoregulation, cell cycle, apoptosis and other signaling pathways may be involved in the development and progression of LGG. Except for HAUS4 and HAUS7, the expression of all genes was positively correlated with immune cell infiltration. High expression of HAUS1, HAUS3, HAUS5, HAUS7, HAUS8 and low expression of HAUS4, HAUS6 in LGG was associated with poor prognosis. The risk models constructed based on the pivotal genes HAUS2, HAUS4 and HAUS8 were validated by nomogram and confirmed to be clinically useful for predicting the prognosis of LGG. - Source: PubMed
Publication date: 2023/05/09
Wang TaoYao SenbangLi SiyuFei XichangZhang Mingjun